Patents Examined by Sun Jae Yoo
  • Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
    Patent number: 11564929
    Abstract: Medicaments for use in treating T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, breast cancer, ovarian cancer, melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumors, adenoid cystic carcinoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, or skin cancer in a patient comprising combination therapy with 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof, and 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: January 31, 2023
    Assignee: Eli Lilly and Company
    Inventors: Bharvin Kumar Patel, Michele C. Smith
  • Pleuromulin 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid ester with antibacterial activity and a method of preparing the same
    Patent number: 11555016
    Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: January 17, 2023
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Yongbo Wang, Han Li, Gennian Mao, Bin Tian, Dan Yang, Chengyuan Liang, Xiuding Yang, Wenbo Yao, Guaiping Qiao, Nan Hui, Juan Li, Liang Xin, Jingyi Li, Ruina Bian
  • Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
    Patent number: 11548893
    Abstract: The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyl, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: January 10, 2023
    Assignee: Arisan Therapeutics Inc.
    Inventors: Michael Bruno Plewe, Kenneth McCormack, Gregory Henkel, Nadezda V. Sokolova, Eric Brown, Vidyasagar Reddy Gantla
  • Nitrated hydrocarbons, derivatives, and processes for their manufacture
    Patent number: 11542277
    Abstract: Provided is a process for the formation of nitrated compounds by the nitration of hydrocarbon compounds with dilute nitric acid. Also provided are processes for preparing industrially useful downstream derivatives of the nitrated compounds, as well as novel nitrated compounds and derivatives, and methods of using the derivatives in various applications.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: January 3, 2023
    Assignee: ANGUS CHEMICAL COMPANY
    Inventors: Daniel M. Trauth, George D. Green, Raymond J. Swedo, Richard L. James, Ian A. Tomlinson
  • Fungicidal oxadiazoles
    Patent number: 11540518
    Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, Z1, W, Z2 and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: January 3, 2023
    Assignee: FMC Corporation
    Inventor: Robert James Pasteris
  • Method for the continuous separation by distillation of mixtures that contain morpholine (MO), monoaminodiglycol (ADG), ammonia, water and methoxyethanol (MOE)
    Patent number: 11518749
    Abstract: A process for the continuous distillative separation of mixtures comprising morpholine (MO), monoaminodiglycol (ADG), ammonia, water and methoxyethanol (MOE), obtained by reacting diethylene glycol (DEG) with ammonia, wherein ammonia, water, ADG and DEG are removed by distillation and the resulting stream comprising MO and MOE is supplied to a distillation column K40 in which at a top pressure of from 20 to 2000 mbar MO, MOE and organic products having a boiling point 128° C. (1.013 bar) are removed via the bottom and organic products having a boiling point 128° C. are removed overhead, and also MO is removed via a side draw, where K40 is equipped with an evaporator for heating the bottoms, into which is fed heating vapor having a pressure of from 1 to 10 bar.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: December 6, 2022
    Assignee: BASF SE
    Inventors: Oliver Bussmann, Eva Koch, Manfred Heilig, Joachim Pfeffinger, Joerg Pastre, Johann-Peter Melder
  • Amide compound, and Pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
    Patent number: 11504379
    Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: November 22, 2022
    Assignees: Hiroshima University, Tokyo University of Pharmacy & Life Sciences, The University of Tokyo
    Inventors: Tomoichiro Asano, Yusuke Nakatsu, Hisanaka Ito, Takayoshi Okabe
  • Method for reducing lung inflammation
    Patent number: 11491126
    Abstract: A method of treating or preventing inflammation in the lung by administering a high concentration of an inhaled chelating agent.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: November 8, 2022
    Assignee: Respirion Pharmaceuticals PTY LTD
    Inventor: Barry Clements
  • Cavitand compositions and methods of use thereof
    Patent number: 11492356
    Abstract: Cavitand compositions that comprise void spaces are disclosed. The void spaces may be empty, which means that voids are free of guest molecules or atoms, or the void spaces may comprise guest molecules or atoms that are normally in their gas phase at standard temperature and pressure. These cavitands may be useful for industrial applications, such as the separation or storage of gasses. Novel cavitand compounds are also disclosed.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: November 8, 2022
    Assignee: Georgetown University
    Inventors: Kevin Travis Holman, Christopher Kane
  • Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators
    Patent number: 11484530
    Abstract: The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: November 1, 2022
    Inventor: Bjoern Colin Kahrs
  • Method for producing N-(hydrocarbon)isocyanuric acid
    Patent number: 11485715
    Abstract: A novel production method enables selective production of an isocyanuric acid N-substituted product of interest in one pot, requiring neither multiple steps nor cumbersome treatment, the method producing an N-(hydrocarbon)isocyanuric acid which includes a step N for reacting, in a solvent, a dihalogenated isocyanuric acid derivative with at least one hydrocarbonization agent selected from the group consisting of a halogenated hydrocarbon compound, a pseudo-halogenated hydrocarbon compound, and a dialkyl sulfate compound.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: November 1, 2022
    Assignee: NISSAN CHEMICAL CORPORATION
    Inventors: Nobuyuki Kakiuchi, Tomohisa Utsunomiya
  • EP4 antagonist
    Patent number: 11479550
    Abstract: A compound represented by general formula (I): (wherein in the formula, all the symbols have the same meanings as those described in the specification), or a pharmaceutically acceptable salt thereof is useful as a medicament's active ingredient having an EP4 receptor antagonistic activity, in preventing and/or treating disease caused by activation of an EP4 receptor.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: October 25, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Asada, Kousuke Tani, Satonori Higuchi
  • Antimalarial hexahydropyrimidine analogues
    Patent number: 11479546
    Abstract: The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: October 25, 2022
    Inventors: Teresa De Haro Garcia, Lloyd Malcolm King, Martin Alexander Lowe, Malcolm Maccoss, Richard David Taylor, Zhaoning Zhu
  • Crystalline salts of peptide epoxyketone immunoproteasome inhibitor
    Patent number: 11479548
    Abstract: Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: October 25, 2022
    Assignee: KEZAR LIFE SCIENCES
    Inventors: Henry Johnson, Evan Lewis, Sean Dalziel, Dustin McMinn
  • Salt of omecamtiv mecarbil and process for preparing salt
    Patent number: 11472773
    Abstract: Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: October 18, 2022
    Assignee: CYTOKINETICS, INC.
    Inventors: Sheng Cui, Henry Morrison, Karthik Nagapudi, Shawn D. Walker, Charles Bernard, Karl Bennett Hansen, Neil Fred Langille, Alan Martin Allgeier, Steven Mennen, Jacqueline C. S. Woo, Bradley Paul Morgan, Alex Muci
  • Guanidine compounds and use thereof
    Patent number: 11465989
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: October 11, 2022
    Assignee: ImmunoMet Therapeutics, Inc.
    Inventors: Sung Wuk Kim, Hong Woo Kim, Sang Hee Yoo, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Young Woo Lee, Mi Jeong Kim, Woong Cho
  • CXCR7 inhibitors for the treatment of cancer
    Patent number: 11464786
    Abstract: Provided herein are methods of treating cancer in an individual in need thereof, the methods comprising administering to the individual a CXCR7 inhibitor. In some embodiments, additional therapeutic agents are used. Also provided herein are methods of preventing precancerous cells expressing FRS2? from developing into cancer, the method comprising administering to an individual having precancerous cells expressing FRS2? a CXCR7 inhibitor. In some embodiments, additional therapeutic agents are used.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: October 11, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Noriko Gotoh, James J. Campbell
  • Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
    Patent number: 11453656
    Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: September 27, 2022
    Assignee: Yuhan Corporation
    Inventors: Sang Ho Oh, Jong Gyun Kim, Se-Woong Oh, Tae Dong Han, Soo Yong Chung, Seong Ran Lee, Kyeong Bae Kim, Young Sung Lee, Woo Seob Shin, Hyun Ju, Jeong Ki Kang, Su Min Park, Dong Kyun Kim
  • Autotaxin inhibitory compounds
    Patent number: 11453666
    Abstract: The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: September 27, 2022
    Assignee: Cancer Research Technology Limited
    Inventors: Martin Lee Stockley, Ellen Catherine Macdonald, Pritom Shah, Allan Jordan, James Hitchin, Niall Hamilton
  • Caspase inhibitor-containing drug for treating or preventing disorders caused by TGF-?, and applications thereof
    Patent number: 11446263
    Abstract: Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-? (TGF-?) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-? signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 20, 2022
    Assignee: The Doshisha
    Inventors: Noriko Koizumi, Naoki Okumura